Eli Lilly's New Obesity Drug Data Sparks Stock Rise Amid Broad Bullish Outlook

SentiSense · Published Sep 14, 2026, 4:09 PM ET · Updated Sep 28, 2026, 2:45 AM ET

Eli Lilly will present fresh Phase 3 data on its oral GLP-1 orforglipron and on retatrutide at a European conference, and Berenberg frames the setup as roughly 21% upside while reiterating full-year 2026 revenue guidance of $85 to $87 billion. The stock rose 1.99% to $1,137.86 on the day, outpacing a 0.48% decline in the S&P 500. Q2 revenue grew 48% to $23 billion on Mounjaro and Zepbound, which together delivered about $14.87 billion, and SentiSense's own analyst consensus puts the average target at $1,324.87 across 29 analysts.

LLY said it will present fresh Phase 3 data on its investigational obesity treatments, the once-daily oral GLP-1 orforglipron and retatrutide, at an upcoming European conference. Berenberg ties the readout to roughly 21% potential upside in the shares and reiterates a full-year 2026 revenue outlook of $85 to $87 billion. Retatrutide has shown what one analysis called near-bariatric efficacy in Phase 3, and prescriber counts for orforglipron jumped from roughly 8,000 to 36,000 in a single quarter.

The market response was immediate. Eli Lilly shares rose 1.99% to $1,137.86 while the S&P 500 fell 0.48% on the same session, a divergence worth noting on a day when rising Treasury yields were pressuring the broader tape. The stock had been trading near $1,120, roughly 13% below its August peak.

The fundamentals underneath the move are the reason the dip drew attention. Q2 revenue rose 48% to $23 billion, with Mounjaro and Zepbound together contributing close to $14.87 billion, and management lifted full-year guidance to $85 to $87 billion against an 86% gross margin expectation. CEO Dave Ricks framed it as momentum continuing. For comparison, Merck grew 5% in the same quarter, with the KEYTRUDA family at $8.4 billion and up just 4% as it approaches peak penetration.

One widely circulated bull argument deserves a caveat. The claim that similar 20% pullbacks have historically been followed by a 48% median gain rests on three events clustered between November 2024 and August 2025, which the source itself describes as one continuous recovery cycle rather than three independent tests, calling it a thin base where a median is not a promise. SentiSense's own analyst consensus currently sits at an average target of $1,324.87 across 29 analysts, with a band from $930.00 to $1,600.00 and a 25 buy / 3 hold / 2 sell split, so the sell side is constructive but not unanimous. What matters next is the European readout itself: efficacy and tolerability data that lands short of expectations could unwind a good deal of the anticipation that has built into the price.